Table 2 Potential use of serological surveys to help inform programmatic response for three anticipated use cases and nine scenarios
Use case/scenario | Seroconversion rate | Programmatic Response/Examples |
---|---|---|
Surveillance for elimination of trachoma after halting MDA or during post-validation (80% prior probability of No action needed) | ||
1 | SCR ≤ 2.2 | No action needed. Morocco-Boumalne Dades-2019 (Fig. 2) |
2 | SCR > 2.2 & <4.5 | No action needed. Additional monitoring may be considered. Morocco-Agdaz-2019 (Fig. 2) |
3 | SCR ≥ 4.5 | Additional monitoring required (clinical, serology, PCR). |
Baseline survey to assess trachoma endemicity (50% prior probability of No action needed) | ||
4 | SCR ≤ 1.6 | No action needed. Togo-Anie-2017, Togo-Keran-2017 (Fig. 2) |
5 | SCR > 1.6 & <3.8 | No action needed. Additional monitoring may be considered. Sudan-Kotom-2019 (Fig. 5) |
6 | SCR ≥ 3.8 | Consider initiating MDA. Sudan-El Seraif-2019, Sudan-Saraf Omrah-2019 (Fig. 5) |
Unusual epidemiology based on clinical and PCR markers (50% prior probability of No action needed) | ||
7 | SCR ≤ 1.6 | Additional monitoring may be considered (serology, PCR) to assess etiology of clinical signs. |
8 | SCR > 1.6 & <3.8 | Additional monitoring may be considered. Ethiopia-Dera-2017 (Table 1, Fig. 5) Vanuatu-Torba/Malampa/Penama/Shefa/Tafea/Sanma-2016 (Table 1, Fig. 5) |
9 | SCR ≥ 3.8 | Additional monitoring required (serology, PCR). |